Worldwide access to Covid-19 vaccine

Tom Buis

A Global Covid-19 Patent Pool could be the solution

Researchers around the world are trying to develop treatments and vaccines against the new Covid-19 virus. This requires huge amounts of public and private funding and cooperation amongst many different organizations. Two potential risks may prevent everyone from accessing the vaccine. Firstly, the lack of sufficient production facilities worldwide. Second, patents on a new vaccine would push up prices, hindering governments from providing them to the public. Costa Rica wants to tackle both issues with a global Covid-19 Patent Pool and has asked the WHO for support.

Nationalism vs solidarity

This week there were rumors that president Trump wanted to lure the German company CureVac to the U.S. CureVac is currently working on a vaccine against Covid-19, and Trump hoped to get his hands on the exclusive rights to the vaccine. The German government prevented the take-over. Whatever is true about these rumors, it’s not time for ‘America First’ or ‘Germany first’, but Global access first.

Global Covid-19 Patent Pool

Costa Rica suggests that a global Covid-19 Patent Pool could be a database of patents and other information like production protocols regarding a new vaccine or treatment. It is inspired on the already existing Medicines Patent Pool. This Covid-19 patent pool would allow all vaccine producers around the world to manufacture a new Covid-19 vaccine, using the patents that are in the patent pool. All the patents would be licensed in a non-exclusive manner. This would mean that we maximize global production capacity. As Wemos we urge other WHO member states to support this letter and to push patent holders into pooling their knowledge in a Covid-19 Patent Pool.

Rewarding innovation

Costa Rica’s letter on pooling of knowledge an intellectual property did not talk about how to reward innovation. As Wemos we think innovation should be rewarded responsibly and in a sustainable manner. A Global Covid-19 Patent Pool model could reward production and innovation through a cost-plus model. On top of the production costs, governments would pay for a transparent and reasonable profit margin. The profit margin is split into two groups; the manufacturers and the patent holders. In order to increase profits, manufacturers would have to increase production. This would be drastically different from the current model of just rising prices.

Governments invest huge amounts of tax payers’ money into research. They could attach conditions to ensure that the public benefits from these investments. For example, by agreeing with research institutions and pharmaceutical companies that in the event that patents are the result of public funding, they should be included in the Global Covid-19 Patent Pool.

A Global Covid-19 Patent Pool as suggested by Costa Rica could be the solution to maximizing access and affordability of a possible new vaccine and deserves all our support. Only with true solidarity and global cooperation we will get through this crisis.

Read more about our work on Access To Medicines.

Photo: Arek Socha (via Pixabay)

Recent Blog items

UHC: time for really ‘innovative’ health financing!

21-12-2020

Myria Koutsoumpa, Rosana Lescrauwaet and Mariska Meurs

This blog was first published on the Health Financing for Africa platform

Ten years after the WHO’s report on Universal Health Coverage (UHC), most African low- and lower-middle income countries are not able to raise enough resources to achieve UHC. And however important, domestic efforts for resource mobilisation alone will not be enough to bring us there. The world has a collective responsibility to address tax injustices and high indebtedness, which have a huge potential to free resources for health.

Continue reading

More engagement and inclusivity in the GFF strategy – a lobby success

26-11-2020

Myria Koutsoumpa

The Global Financing Facility (GFF) – a global health initiative aiming to end preventable deaths and improve the life of women, children, and adolescents in low- and middle-income countries – is evolving. Continuous lobby and advocacy by civil society has influenced its direction, making it more inclusive. In this blog, we will elaborate on how Wemos influenced the new strategy of this major global health initiative in collaboration with our partners and networks.

Continue reading